Comparative Pharmacology
Head-to-head clinical analysis: RENESE versus TRICHLORMETHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RENESE versus TRICHLORMETHIAZIDE.
RENESE vs TRICHLORMETHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption, leading to increased diuresis and vasodilation.
Inhibits sodium-chloride symporter in distal convoluted tubule, increasing excretion of sodium, chloride, and water.
Initial 2.5-5 mg orally once daily; increase by 2.5-5 mg every 2-4 weeks up to 20 mg/day as needed.
2-4 mg orally once daily; maximum 4 mg/day.
None Documented
None Documented
13–15 hours; prolonged in renal impairment (CrCl <30 mL/min: up to 30–40 hours).
Clinical Note
moderateTrichlormethiazide + Digoxin
"The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Digoxin."
Clinical Note
moderateTrichlormethiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Digitoxin."
Clinical Note
moderateTrichlormethiazide + Deslanoside
"The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Deslanoside."
Clinical Note
moderateTerminal elimination half-life is approximately 2-6 hours (average 3.5 h); clinical context: short half-life necessitates once or twice daily dosing for sustained diuresis.
Renal: ~85% unchanged; fecal: ~15% (via bile).
Primarily renal (tubular secretion); ~70% excreted unchanged in urine; minor biliary/fecal (<10% total).
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic
Trichlormethiazide + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Acetyldigitoxin."